Name | 3-(4-Chlorbutyl)-1H-indol-5-carbonitrile |
Synonyms | Vilazodone Intermediate 8 InterMediate of Vilazodone 3-(4-chloro-butyl)-5-cyanoindole Vilazodone Hydrochloride Intermediate 3-(4-Chlorobutyl)indole-5-carbonitrile 3-(4-Chlorbutyl)-1H-indol-5-carbonitril Chlorobutyl)indole-5-carbonitrile, 3-(4- 3-(4-Chlorbutyl)-1H-indol-5-carbonitrile 3-(4-chlorobutyl)-1H-indole-5-carbonitrile 1H-Indole-5-carbonitrile, 3-(4-chlorobutyl)- |
CAS | 143612-79-7 |
EINECS | 801-938-0 |
InChI | InChI=1S/C13H13ClN2/c14-6-2-1-3-11-9-16-13-5-4-10(8-15)7-12(11)13/h4-5,7,9,16H,1-3,6H2 |
Molecular Formula | C13H13ClN2 |
Molar Mass | 232.71 |
Density | 1.22 |
Melting Point | 99-100℃ |
Boling Point | 448.1±35.0 °C(Predicted) |
Solubility | Chloroform (Slightly, Ethyl Acetate (Slightly) |
Appearance | Solid |
Color | Off-White to Pale Beige |
pKa | 15.93±0.30(Predicted) |
Storage Condition | under inert gas (nitrogen or Argon) at 2-8°C |
Use | 3-(4-chlorobutyl)-5-cyanoindole is used in the preparation of allosteric IGF-1R inhibitors, used as a bis5-HT1A receptor agonist Reactants and serotonin reuptake inhibitors. |
Synthesis method | 3-(4-chlorobutyl)-5-cyanoindole can be obtained by acylation and reduction of 5-cyanoindole and 4-chlorobutyryl chloride. First, 5-cyanoindole and 4-chlorobutyryl chloride were used as raw materials, dichloromethane was used as solvent, and chlorobutyryl-substituted 5-cyanoindole was obtained by F-C acylation under the catalysis of isobutylaluminum dichloride (yield 82%). Later, in methylene chloride, isobutyl aluminum dichloride was used as a catalyst, and sodium borohydride was used as a reducing agent to successfully synthesize the target compound 3-(4-chlorobutyl)-5-cyanoindole. |
Application | 3-(4-chlorobutyl)-5-cyanoindole is a key intermediate in the synthesis of vilazodone, mainly used for synthesis of vilazodone, such as 3-(4-chlorobutyl)-1H-indole-5-cyano as the key intermediate to prepare vilazodone hydrochloride method. |
overview | depression is a common mental disease, its clinical symptoms are low mood, sleep restlessness, slow thinking, loss of interest and loss of appetite. According to a report released by the World Health Organization on October 9, 2012, more than 0.35 billion people worldwide suffer from depression of varying degrees. About 1/3 of the world's annual suicides are accompanied by depressive symptoms. Depression has become a social public health problem that needs urgent attention and urgent solution. The cause of depression is not yet fully clear. It is generally believed to be caused by psychological and biological factors (including neurotransmitter etiology and genetic etiology, etc.). The different pathogenesis of depression also determines the different treatment methods, which are generally divided into two categories: drug treatment and non-drug treatment. Symptoms caused by psychological problems can be alleviated by a variety of non-drug methods such as rational therapy, behavioral therapy, and art therapy. Depression caused by neurotransmitter disorders or genetic factors needs to be treated with corresponding drugs. At present, Western medicine treatment is the leading. |